Sermorelin

Sermorelin (GHRH 1-29) Synthetic Growth Hormone-Releasing Hormone Fragment | Research Use Only

Sermorelin is a synthetic peptide corresponding to the biologically active N-terminal 29 amino acid fragment of endogenous growth hormone-releasing hormone (GHRH 1-29-NH₂). As the shortest GHRH fragment retaining full receptor binding activity at the GHRH receptor (GHRHR), Sermorelin has been extensively utilized as a research tool in studies examining the somatotropic axis and pituitary biology.

In laboratory and preclinical research models, Sermorelin has been investigated for its interactions with GHRH receptor pharmacology, pituitary somatotroph cell signaling, and growth hormone secretion mechanisms. Research applications include studies of the GH/IGF-1 axis, hypothalamic-pituitary function models, and metabolic pathway investigations. Additional research areas include body composition studies in animal models, cardiovascular biology investigations, sleep architecture research in relation to somatotropic signaling, and neuroprotective pathway studies. Sermorelin serves as a widely employed reference compound in comparative GHRH receptor agonist pharmacology research.

Research Specifications:

• Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
• Molecular Weight: ~3357.9 g/mol
• CAS Number: 86168-78-7
• Purity: ≥98% (HPLC verified)
• Form: Lyophilized powder
• Storage: -20°C, protected from light and moisture

For Research Use Only. This product is not intended for human or veterinary use, diagnosis, or treatment. Not evaluated by the FDA. For qualified research applications only.